{
  "respiratory_asthma_india": {
    "therapy_area": "Respiratory - Asthma",
    "country": "India",
    "historical_market_size_usd_mn": {
      "2019": 780,
      "2020": 860,
      "2021": 940,
      "2022": 1020,
      "2023": 1085,
      "2024": 1120
    },
    "forecast_market_size_usd_mn": {
      "2025": 1240,
      "2026": 1385,
      "2027": 1560,
      "2028": 1698
    },
    "cagr_percent_2024_2028": 10.8,
    "competitor_count": 42,
    "brand_leaders": [
      { "brand": "Seroflo", "company": "Cipla", "market_share_percent": 28 },
      { "brand": "Foracort", "company": "Sun Pharma", "market_share_percent": 22 },
      { "brand": "Symbicort", "company": "AstraZeneca", "market_share_percent": 12 }
    ],
    "epi_data": {
      "prevalence_mn": 39,
      "incidence_mn": 5.8,
      "pediatric_percent": 34,
      "urban_burden_percent": 41,
      "mortality_rate_per_100k": 6.1
    },
    "drivers": [
      "Rising pediatric asthma diagnosis",
      "Urban pollution growth",
      "Strong generic penetration"
    ],
    "barriers": [
      "Low adoption of advanced inhalation devices",
      "Affordability variations across states"
    ],
    "rx_volume_mn": 154.3,
    "unmet_need_score": 7.4,
    "innovation_opportunities": [
      "Pediatric-friendly inhalers",
      "Fixed-dose steroid combinations with fewer side effects",
      "Breath-actuated device variants"
    ]
  },

  "respiratory_copd_india": {
    "therapy_area": "Respiratory - COPD",
    "country": "India",
    "historical_market_size_usd_mn": {
      "2019": 510,
      "2020": 545,
      "2021": 592,
      "2022": 640,
      "2023": 710,
      "2024": 760
    },
    "forecast_market_size_usd_mn": {
      "2025": 845,
      "2026": 930,
      "2027": 1040,
      "2028": 1155
    },
    "cagr_percent_2024_2028": 10.9,
    "competitor_count": 35,
    "brand_leaders": [
      { "brand": "Tiova", "company": "Cipla", "market_share_percent": 31 },
      { "brand": "Duolin", "company": "Cipla", "market_share_percent": 18 },
      { "brand": "Spiriva", "company": "Boehringer Ingelheim", "market_share_percent": 11 }
    ],
    "epi_data": {
      "prevalence_mn": 18,
      "incidence_mn": 2.7,
      "smoker_percent": 47,
      "rural_burden_percent": 58,
      "mortality_rate_per_100k": 12.4
    },
    "drivers": [
      "High smoking rates",
      "Ageing population",
      "Rising diagnosis rates"
    ],
    "barriers": [
      "Low spirometry penetration",
      "Awareness gaps in rural regions"
    ],
    "rx_volume_mn": 98.6,
    "unmet_need_score": 8.1,
    "innovation_opportunities": [
      "Long-acting nebulized formulations",
      "Once-daily triple therapy FDCs",
      "Digital inhaler adherence tools"
    ]
  },

  "diabetes_type2_india": {
    "therapy_area": "Diabetes Type 2",
    "country": "India",
    "historical_market_size_usd_bn": {
      "2019": 3.4,
      "2020": 3.9,
      "2021": 4.2,
      "2022": 4.9,
      "2023": 5.5,
      "2024": 5.9
    },
    "forecast_market_size_usd_bn": {
      "2025": 6.7,
      "2026": 7.8,
      "2027": 9.2,
      "2028": 10.6
    },
    "cagr_percent_2024_2028": 15.6,
    "competitor_count": 65,
    "epi_data": {
      "prevalence_mn": 78,
      "undiagnosed_percent": 42,
      "obesity_association_percent": 61
    },
    "brand_leaders": [
      { "brand": "Janumet", "company": "MSD", "market_share_percent": 12 },
      { "brand": "Glyxambi", "company": "Boehringer", "market_share_percent": 8 }
    ],
    "rx_volume_mn": 310,
    "unmet_need_score": 7.9,
    "innovation_opportunities": [
      "Low-cost GLP-1 analogues",
      "Once-weekly oral formulations",
      "Affordable cardioprotective FDCs"
    ]
  },

  "cv_heart_failure_global": {
    "therapy_area": "Heart Failure",
    "country": "Global",
    "historical_market_size_usd_bn": {
      "2019": 12.1,
      "2020": 13.3,
      "2021": 15.2,
      "2022": 16.8,
      "2023": 18.4,
      "2024": 20.1
    },
    "forecast_market_size_usd_bn": {
      "2025": 23.2,
      "2026": 26.7,
      "2027": 31.1,
      "2028": 36.8
    },
    "cagr_percent_2024_2028": 16.2,
    "competitor_count": 28,
    "brand_leaders": [
      { "brand": "Entresto", "company": "Novartis", "market_share_percent": 41 },
      { "brand": "Farxiga", "company": "AstraZeneca", "market_share_percent": 19 }
    ],
    "epi_data": {
      "prevalence_mn": 64,
      "annual_incidence_mn": 4.3,
      "mortality_5yr_percent": 50
    },
    "drivers": [
      "SGLT-2 adoption",
      "Increased HF diagnosis",
      "New guideline updates"
    ],
    "barriers": [
      "Cost barriers in emerging markets",
      "Complex titration regimens"
    ],
    "unmet_need_score": 8.5,
    "innovation_opportunities": [
      "Once-daily FDC for HF",
      "Simplified titration solutions"
    ]
  },

  "infectious_diseases_latam": {
    "therapy_area": "Infectious Diseases",
    "country": "LATAM",
    "historical_market_size_usd_bn": {
      "2019": 4.1,
      "2020": 4.4,
      "2021": 4.7,
      "2022": 5.1,
      "2023": 5.9,
      "2024": 6.5
    },
    "forecast_market_size_usd_bn": {
      "2025": 7.4,
      "2026": 8.8,
      "2027": 10.5,
      "2028": 12.1
    },
    "cagr_percent_2024_2028": 16.4,
    "infectious_hotspots": [
      "Dengue",
      "TB",
      "Hepatitis B",
      "Community-acquired pneumonia"
    ],
    "competitor_density": "Low",
    "multinational_presence_low": true,
    "unmet_need_score": 9.2
  }
}
